Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.935
-0.035 (-1.78%)
Apr 23, 2026, 2:21 PM EDT - Market open
Esperion Therapeutics Employees
Esperion Therapeutics had 294 employees as of December 31, 2025. The number of employees decreased by 10 or -3.29% compared to the previous year.
Employees
294
Change (1Y)
-10
Growth (1Y)
-3.29%
Revenue / Employee
$1,371,207
Profits / Employee
-$77,150
Market Cap
498.08M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 294 | -10 | -3.29% |
| Dec 31, 2024 | 304 | 64 | 26.67% |
| Dec 31, 2023 | 240 | 41 | 20.60% |
| Dec 31, 2022 | 199 | -19 | -8.72% |
| Dec 31, 2021 | 218 | -261 | -54.49% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Evolus | 334 |
| Akebia Therapeutics | 194 |
| Aquestive Therapeutics | 147 |
| Ironwood Pharmaceuticals | 100 |
ESPR News
- 6 hours ago - Esperion to Report First Quarter 2026 Financial Results on May 7 - GlobeNewsWire
- 20 days ago - Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - GlobeNewsWire
- 20 days ago - Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - GlobeNewsWire
- 5 weeks ago - Esperion's Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia - GlobeNewsWire
- 6 weeks ago - Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 7 weeks ago - Esperion Therapeutics and Corstasis Therapeutics Announce Esperion's Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - Business Wire
- 2 months ago - Esperion to Participate in The 2026 Citizens Life Sciences Conference - GlobeNewsWire
- 2 months ago - Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040 - GlobeNewsWire